 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 3,305 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Submission declined on 22 May 2024 by Notcharizard (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
Comment: None of the sources are primarily about him. -- NotCharizard 🗨 04:33, 22 May 2024 (UTC)
David Ridley | |
|---|---|
| Alma mater | Duke University (PhD) University of Missouri-Columbia (BS) |
| Known for | priority review voucher, vector expedited review voucher, health economics |
| Scientific career | |
| Institutions | Duke University |
| Website | Personal webpage |
David Ridley is a health economist and the Faculty Director for the Center for Health Sector Management at Duke University's Fuqua School of Business.[1] His most influential research focuses on the economics of innovative medical products, particularly the development, manufacturing, and pricing of pharmaceuticals.[2]
Career
editRidley's research has had a significant effect on public policy. He was the lead author of two articles that became law in the United States.[3]
In 2006, Ridley with Jeffrey Moe and Henry Grabowski, proposed the Food and Drug Administration's priority review voucher program.[4] The voucher program became law in the Food and Drug Administration Amendments Act (FDAAA) of 2007.[5] Ridley was the subject of a profile in the Wall Street Journal, "Medical Miracles From FDA Inefficiency", which explored his career, research, and the significant impacts of the voucher program on drug development for rare diseases.[6]
In 2015, Ridley, Jeffrey Moe, and Nick Hamon proposed the Environmental Protection Agency's vector expedited review voucher (VERV) program.[7] It became law seven years later in the Pesticide Registration and Improvement Act of 2022.[8]
Since 2013, Ridley has served as the Faculty Director for the Center for Health Sector Management,[9] one of the largest health sector programs at a leading business school.[10]
Ridley also teaches and mentors students. He was named a favorite business school MBA professor in Poets and Quants in 2016,[11] 2021,[12] and 2022.[13]
References
edit- ^ "David Ridley, PhD – Duke Health Sector Advisory Council". Retrieved 2024-05-28.
- ^ "David Ridley". CEPR. 2017-11-02. Retrieved 2024-05-28.
- ^ "David Ridley | Duke's Fuqua School of Business". www.fuqua.duke.edu. Retrieved 2024-05-28.
- ^ Ridley, David B.; Grabowski, Henry G.; Moe, Jeffrey L. (2006-03-01). "Developing Drugs For Developing Countries". Health Affairs. 25 (2): 313–324. doi:10.1377/hlthaff.25.2.313. ISSN 0278-2715. PMID 16522573.
- ^ John, Dingell (2007-09-27). "Cosponsors - H.R.3580 - 110th Congress (2007-2008): Food and Drug Administration Amendments Act of 2007". www.congress.gov.
- ^ Finley, Allysia. "Medical Miracles From FDA Inefficiency". WSJ. Retrieved 2024-05-22.
- ^ Ridley, David B.; Moe, Jeffrey L.; Hamon, Nick (2017-08-01). "A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases". Health Affairs. 36 (8): 1461–1468. doi:10.1377/hlthaff.2016.1640. ISSN 0278-2715. PMID 28784739.
- ^ "Vector Expedited Review Voucher (VERV) Program". OCSPP. US EPA. 2023-12-20. Retrieved 2024-05-22.
- ^ "HSM Faculty | HSM". centers.fuqua.duke.edu. Retrieved 2024-05-22.
- ^ "History | HSM". centers.fuqua.duke.edu. Retrieved 2024-05-22.
- ^ Schmitt, Jeff (2016-08-17). "Favorite Business School MBA Professors". Poets&Quants. Retrieved 2024-05-22.
- ^ Schmitt, Jeff (2021-07-03). "2021 MBAs To Watch: Sarah Izzo, Duke University (Fuqua)". Poets&Quants. Retrieved 2024-05-22.
- ^ Schmitt, Jeff (2022-09-06). "2022 MBA To Watch: Jordan Daniel Lantz, Duke University (Fuqua)". Poets&Quants. Retrieved 2024-05-22.
External links
edit